The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans

Arash Kazemi, Jay W. McLaren, Casey C. Kopczynski, Theresa G. Heah, Gary D. Novack, Arthur J Sit

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose: Netarsudil, an inhibitor of Rho kinase and a norepinephrine transporter, has been shown to lower elevated intraocular pressure (IOP) in controlled studies of patients with open-angle glaucoma and ocular hypertension, and in healthy volunteers. The mechanism of this ocular hypotensive effect in humans is unknown. Methods: The objective of this study was to evaluate the effect of netarsudil 0.02% on aqueous humor dynamics (AHD) parameters. In this double-masked, vehicle-controlled, paired-eye comparison study, 11 healthy volunteers received topical netarsudil ophthalmic solution 0.02% or its vehicle once daily for 7 days (morning dosing). The primary endpoints were the change in AHD parameters, compared between active and vehicle-treated eyes. Results: In netarsudil-treated eyes, diurnal outflow facility increased from 0.27 ± 0.10 μL/min/mmHg to 0.33 ± 0.11 μL/min/mmHg (+22%; P = 0.02) after 7 days of treatment. In placebo-treated eyes, diurnal outflow facility did not significantly change (P = 0.94). The difference between netarsudil and placebo eyes in diurnal change of outflow facility was 0.08 μL/min/mmHg (P < 0.001). Diurnal episcleral venous pressure (EVP) in netarsudil-treated eyes decreased from 7.9 ± 1.2 mmHg to 7.2 ± 1.8 (-10%; P = 0.01). Diurnal EVP was not significantly different between netarsudil- A nd placebo-treated eyes. There was a trend toward decreasing aqueous humor flow rate (-15%; P = 0.08). No treatment changes were seen in uveoscleral outflow rate. Conclusions: Once-daily dosing of netarsudil ophthalmic solution 0.02% lowered IOP through increasing trabecular outflow facility and reducing EVP. This suggests a combination of mechanisms that affect both the proximal and distal outflow pathways.

Original languageEnglish (US)
Pages (from-to)380-386
Number of pages7
JournalJournal of Ocular Pharmacology and Therapeutics
Volume34
Issue number5
DOIs
StatePublished - Jun 1 2018

Fingerprint

Aqueous Humor
Ophthalmic Solutions
Venous Pressure
Placebos
Intraocular Pressure
Healthy Volunteers
Norepinephrine Plasma Membrane Transport Proteins
Matched-Pair Analysis
rho-Associated Kinases
Ocular Hypertension
Open Angle Glaucoma
Therapeutics

Keywords

  • aqueous humor dynamics
  • glaucoma
  • netarsudil
  • outflow

ASJC Scopus subject areas

  • Ophthalmology
  • Pharmacology
  • Pharmacology (medical)

Cite this

The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans. / Kazemi, Arash; McLaren, Jay W.; Kopczynski, Casey C.; Heah, Theresa G.; Novack, Gary D.; Sit, Arthur J.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 34, No. 5, 01.06.2018, p. 380-386.

Research output: Contribution to journalArticle

Kazemi, Arash ; McLaren, Jay W. ; Kopczynski, Casey C. ; Heah, Theresa G. ; Novack, Gary D. ; Sit, Arthur J. / The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans. In: Journal of Ocular Pharmacology and Therapeutics. 2018 ; Vol. 34, No. 5. pp. 380-386.
@article{83b2e9beb37040fa905556b1d23b7be7,
title = "The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans",
abstract = "Purpose: Netarsudil, an inhibitor of Rho kinase and a norepinephrine transporter, has been shown to lower elevated intraocular pressure (IOP) in controlled studies of patients with open-angle glaucoma and ocular hypertension, and in healthy volunteers. The mechanism of this ocular hypotensive effect in humans is unknown. Methods: The objective of this study was to evaluate the effect of netarsudil 0.02{\%} on aqueous humor dynamics (AHD) parameters. In this double-masked, vehicle-controlled, paired-eye comparison study, 11 healthy volunteers received topical netarsudil ophthalmic solution 0.02{\%} or its vehicle once daily for 7 days (morning dosing). The primary endpoints were the change in AHD parameters, compared between active and vehicle-treated eyes. Results: In netarsudil-treated eyes, diurnal outflow facility increased from 0.27 ± 0.10 μL/min/mmHg to 0.33 ± 0.11 μL/min/mmHg (+22{\%}; P = 0.02) after 7 days of treatment. In placebo-treated eyes, diurnal outflow facility did not significantly change (P = 0.94). The difference between netarsudil and placebo eyes in diurnal change of outflow facility was 0.08 μL/min/mmHg (P < 0.001). Diurnal episcleral venous pressure (EVP) in netarsudil-treated eyes decreased from 7.9 ± 1.2 mmHg to 7.2 ± 1.8 (-10{\%}; P = 0.01). Diurnal EVP was not significantly different between netarsudil- A nd placebo-treated eyes. There was a trend toward decreasing aqueous humor flow rate (-15{\%}; P = 0.08). No treatment changes were seen in uveoscleral outflow rate. Conclusions: Once-daily dosing of netarsudil ophthalmic solution 0.02{\%} lowered IOP through increasing trabecular outflow facility and reducing EVP. This suggests a combination of mechanisms that affect both the proximal and distal outflow pathways.",
keywords = "aqueous humor dynamics, glaucoma, netarsudil, outflow",
author = "Arash Kazemi and McLaren, {Jay W.} and Kopczynski, {Casey C.} and Heah, {Theresa G.} and Novack, {Gary D.} and Sit, {Arthur J}",
year = "2018",
month = "6",
day = "1",
doi = "10.1089/jop.2017.0138",
language = "English (US)",
volume = "34",
pages = "380--386",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans

AU - Kazemi, Arash

AU - McLaren, Jay W.

AU - Kopczynski, Casey C.

AU - Heah, Theresa G.

AU - Novack, Gary D.

AU - Sit, Arthur J

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Purpose: Netarsudil, an inhibitor of Rho kinase and a norepinephrine transporter, has been shown to lower elevated intraocular pressure (IOP) in controlled studies of patients with open-angle glaucoma and ocular hypertension, and in healthy volunteers. The mechanism of this ocular hypotensive effect in humans is unknown. Methods: The objective of this study was to evaluate the effect of netarsudil 0.02% on aqueous humor dynamics (AHD) parameters. In this double-masked, vehicle-controlled, paired-eye comparison study, 11 healthy volunteers received topical netarsudil ophthalmic solution 0.02% or its vehicle once daily for 7 days (morning dosing). The primary endpoints were the change in AHD parameters, compared between active and vehicle-treated eyes. Results: In netarsudil-treated eyes, diurnal outflow facility increased from 0.27 ± 0.10 μL/min/mmHg to 0.33 ± 0.11 μL/min/mmHg (+22%; P = 0.02) after 7 days of treatment. In placebo-treated eyes, diurnal outflow facility did not significantly change (P = 0.94). The difference between netarsudil and placebo eyes in diurnal change of outflow facility was 0.08 μL/min/mmHg (P < 0.001). Diurnal episcleral venous pressure (EVP) in netarsudil-treated eyes decreased from 7.9 ± 1.2 mmHg to 7.2 ± 1.8 (-10%; P = 0.01). Diurnal EVP was not significantly different between netarsudil- A nd placebo-treated eyes. There was a trend toward decreasing aqueous humor flow rate (-15%; P = 0.08). No treatment changes were seen in uveoscleral outflow rate. Conclusions: Once-daily dosing of netarsudil ophthalmic solution 0.02% lowered IOP through increasing trabecular outflow facility and reducing EVP. This suggests a combination of mechanisms that affect both the proximal and distal outflow pathways.

AB - Purpose: Netarsudil, an inhibitor of Rho kinase and a norepinephrine transporter, has been shown to lower elevated intraocular pressure (IOP) in controlled studies of patients with open-angle glaucoma and ocular hypertension, and in healthy volunteers. The mechanism of this ocular hypotensive effect in humans is unknown. Methods: The objective of this study was to evaluate the effect of netarsudil 0.02% on aqueous humor dynamics (AHD) parameters. In this double-masked, vehicle-controlled, paired-eye comparison study, 11 healthy volunteers received topical netarsudil ophthalmic solution 0.02% or its vehicle once daily for 7 days (morning dosing). The primary endpoints were the change in AHD parameters, compared between active and vehicle-treated eyes. Results: In netarsudil-treated eyes, diurnal outflow facility increased from 0.27 ± 0.10 μL/min/mmHg to 0.33 ± 0.11 μL/min/mmHg (+22%; P = 0.02) after 7 days of treatment. In placebo-treated eyes, diurnal outflow facility did not significantly change (P = 0.94). The difference between netarsudil and placebo eyes in diurnal change of outflow facility was 0.08 μL/min/mmHg (P < 0.001). Diurnal episcleral venous pressure (EVP) in netarsudil-treated eyes decreased from 7.9 ± 1.2 mmHg to 7.2 ± 1.8 (-10%; P = 0.01). Diurnal EVP was not significantly different between netarsudil- A nd placebo-treated eyes. There was a trend toward decreasing aqueous humor flow rate (-15%; P = 0.08). No treatment changes were seen in uveoscleral outflow rate. Conclusions: Once-daily dosing of netarsudil ophthalmic solution 0.02% lowered IOP through increasing trabecular outflow facility and reducing EVP. This suggests a combination of mechanisms that affect both the proximal and distal outflow pathways.

KW - aqueous humor dynamics

KW - glaucoma

KW - netarsudil

KW - outflow

UR - http://www.scopus.com/inward/record.url?scp=85048387092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048387092&partnerID=8YFLogxK

U2 - 10.1089/jop.2017.0138

DO - 10.1089/jop.2017.0138

M3 - Article

C2 - 29469601

AN - SCOPUS:85048387092

VL - 34

SP - 380

EP - 386

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 5

ER -